Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 5/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | JAK3 | P52333 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 2/20 | 0.34 |
| ▸ | KRAS | P01116 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21303477 | 0.91 | BTK (0.39) | CYP2D6CYP1A2CYP2C9ALDH1A1HRH3 | |
| SCHEMBL16074977 | 0.91 | BTK (0.39) | CYP2D6CYP1A2CYP2C9ALDH1A1HRH3 | |
| SCHEMBL15474352 | 0.86 | BTK (0.41) | JAK3BTKKRAS | |
| SCHEMBL16380178 | 0.83 | GRM5 (0.41) | CYP2D6CYP1A2CYP2C9ALDH1A1GRM5 | |
| SCHEMBL16375283 | 0.83 | KMT2A (0.40) | CYP1A2CYP2C9HRH3JAK3BTK | |
| SCHEMBL18256134 | 0.83 | CYP2D6 (0.49) | CYP2D6CYP1A2CYP2C9ALDH1A1GRM5 | |
| SCHEMBL26294933 | 0.81 | BTK (0.36) | HRH3JAK3BTKKRAS | |
| SCHEMBL16375282 | 0.80 | JAK3 (0.35) | HRH3JAK3BTKKRAS | |
| SCHEMBL29724136 | 0.79 | GRM5 (0.47) | CYP2D6CYP1A2CYP2C9ALDH1A1GRM5 | |
| SCHEMBL16375288 | 0.79 | HRH3 (0.41) | CYP2D6CYP1A2CYP2C9ALDH1A1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828364-B2 | Pyrazole compounds as BTK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-11-28 | — | — | US | disclosed |
| US-9828364-B2 | Pyrazole compounds as BTK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-11-28 | — | — | US | disclosed |
| US-20160340339-A1 | PYRAZOLE COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-11-24 | — | — | US | disclosed |
| US-20160340339-A1 | PYRAZOLE COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-11-24 | — | — | US | disclosed |
| US-9458162-B2 | Cyclic molecules as bruton's tyrosine kinase inhibitors | NANJING ALLGEN PHARMA CO. LTD. (CN) | 2016-10-04 | — | — | US | disclosed |
| US-20150011530-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITORS | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340339-A1 | PYRAZOLE COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LYN | CYP2D6 930/4885CYP1A2 1149/4885CYP2C9 600/4885 |
| US-20150011530-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITORS | ABL1, BTK, PRKACA | CYP2D6 3779/4885CYP1A2 4029/4885CYP2C9 3137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.